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Urinary exosomes containing apical membrane and
intracellular fluid are normally secreted into the urine from all
nephron segments, and may carry protein markers of renal
dysfunction and structural injury. We aimed to discover
biomarkers in urinary exosomes to detect acute kidney
injury (AKI), which has a high mortality and morbidity.
Animals were injected with cisplatin. Urinary exosomes
were isolated by differential centrifugation. Protein changes
were evaluated by two-dimensional difference in gel
electrophoresis and changed proteins were identified by
mass spectrometry. The identified candidate biomarkers
were validated by Western blotting in individual urine
samples from rats subjected to cisplatin injection; bilateral
ischemia and reperfusion (I/R); volume depletion; and
intensive care unit (ICU) patients with and without AKI. We
identified 18 proteins that were increased and nine proteins
that were decreased 8 h after cisplatin injection. Most of the
candidates could not be validated by Western blotting.
However, exosomal Fetuin-A increased 52.5-fold at day 2
(1 day before serum creatinine increase and tubule damage)
and remained elevated 51.5-fold at day 5 (peak renal injury)
after cisplatin injection. By immunoelectron microscopy and
elution studies, Fetuin-A was located inside urinary
exosomes. Urinary Fetuin-A was increased 31.6-fold in the
early phase (2–8 h) of I/R, but not in prerenal azotemia.
Urinary exosomal Fetuin-A also increased in three ICU
patients with AKI compared to the patients without AKI. We
conclude that (1) proteomic analysis of urinary exosomes can
provide biomarker candidates for the diagnosis of AKI and
(2) urinary Fetuin-A might be a predictive biomarker of
structural renal injury.
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Acute kidney injury (AKI) still has a high morbidity and
mortality rate of 25–70%.1 Although numerous agents are
effective in animals, the translation of an effective drug
therapy for AKI from laboratory bench to beside has been
difficult.1–4 Novel biomarkers for early detection and accurate
diagnosis of AKI will likely help speed the translation of new
treatments for AKI. To achieve this goal, the development of
novel non-invasive biomarkers to predict and evaluate
severity of AKI is essential.4,5
Serum creatinine (SCr) has poor sensitivity and specificity
to detect or grade the severity of AKI: patients are not in
steady state, hence SCr lags behind both renal injury and
renal recovery.3 Urine is an ideal non-invasive source of
biomarkers to diagnose and classify kidney diseases. How-
ever, conventional urine markers (casts, fractional excretion
of sodium) are nonspecific and insensitive. Recently, we
successfully isolated exosomes from human urine by
differential centrifugation and demonstrated the presence of
several disease-related proteins.6,7 Exosomes containing
vesicular membranes and intracellular fluid are normally
secreted into the urine from all nephron segments, and
contain proteins that may be altered in abundance or physical
properties in association with various renal diseases. Urinary
exosomes represent a new source for the discovery of non-
invasive urinary biomarkers that can overcome much of the
interference from the most abundant urinary proteins
(albumin, globulin, and Tamm–Horsfall protein, etc).8
Recently, several novel urinary biomarkers have been
discovered using genomic methods as potentially useful
for prediction and diagnosis of AKI. Kidney injury mole-
cule-17,9,10 and neutrophil gelatinase-associated lipocalin
(NGAL)11–14 have been demonstrated as early predictors for
diagnosis or outcome in AKI patients and animal models.
Interleukin-1815,16 sodium/hydrogen exchanger isoform 317
and cystatin C18 have also been verified to serve as
biomarkers in small numbers of patients with AKI. Cysteine
rich protein 61,19 dendrimer-enhanced magnetic resonance
imaging,20 malondialdehyde,21 keratinocyte-derived chemo-
kine,22 and meprin-1-alpha23 have been reported to early
detect renal injury in AKI animal models. Because these
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biomarkers have only been validated for animals with AKI or
a small number of patients, their translation to clinical
application still needs further development and each
biomarker currently has limitations.5 Additional new urinary
biomarkers may be required to improve early detection and
new drug development in AKI.
The purpose of the present study was to discover new
biomarker candidates for AKI. For this purpose, we selected a
cis-diammineplatium (II) dichloride (cisplatin)-induced AKI
rat model, which is non-oliguric despite nephrotoxic tubular
injury, for discovery of biomarkers in urinary exosomes. After
the identification by mass spectrometry, we validated the
potential candidates using Western blotting. We selected
Fetuin-A, which is synthesized in liver and secreted into
blood, to examine its temporal excretion in the urinary
exosomal fraction in different types of AKI animal models to
verify whether it can predict the occurrence of structural
renal injury. We also measured urinary exosomal Fetuin-A in
a small number of intensive care unit (ICU) patients with
and without AKI for a preliminary assessment of the
potential of this biomarker.
RESULTS
Induction of AKI
Cisplatin injection (6 mg/kg, intravenously) induced a
significant increase in SCr and renal morphological damage
including extensive tubular damage and intra-tubular cast
formation in the outer stripe of the outer medulla (OSOM).
SCr and blood urea nitrogen increased significantly by day 3,
reached a peak at day 5, and then gradually returned to the
basal value by day 14 (Figure 1a and b). Tubule morphology
was normal on day 2, the brush border began to detach at day
3, tubular damage was most severe at day 5, and then
gradually recovered thereafter (Figure 2a–e). However, renal
function and histology was still normal at 2 days after
cisplatin injection.
Bilateral ischemia for 37 min and reperfusion (I/R)
increased SCr (from 0.4770.04 to 1.070.42 mg/dl at 8 h,
1.5770.22 mg/dl at 24 h after I/R) and caused tubular
damage in the OSOM in kidney detectable at 8 and 24 h
(Figure 2f and g).
In contrast, a prerenal azotemia model generated by
furosemide and low-sodium diet caused volume depletion
(VD), weight loss (9.6970.99%), and moderately increased
SCr (0.6370.04 vs 0.4570.04 mg/dl before treatment). No
renal histology changes were detected (not shown).
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Figure 1 | SCr and blood urea nitrogen in cisplatin-induced AKI
in rats (n¼ 56). (a) SCr and (b) blood urea nitrogen increased
significantly on day 3, peaked at day 5, and returned to baseline
at day 14 after cisplatin injection. Data are means7s.e.m. *Po0.01,
#Po0.05 vs day 0.
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Figure 2 | Histology of the kidney sections stained with periodic
acid-Schiff reagent in the OSOM after renal injury. Temporal
morphologic change of OSOM (a) before, and at (b) day 1, (c) day 2,
(d) day 3, and (e) day 5 after cisplatin injection. Kidney (f) 8 h and
(g) 24 h reperfusion after 37 min of bilateral ischemia. Original
magnification 400.
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Identification and validation of urinary exosomes-associated
proteins
Cy dye-labeled urinary exosome-associated proteins were
separated by two-dimensional difference in gel electrophor-
esis (2D-DIGE) (Figure 3a). The DeCyder (Biological
Variation Analysis) software recognized 1769 spots; 19.4%
increased by at least 1.5-fold and 13.3% decreased by at least
1.5-fold after cisplatin injection. Only 74 spots had (1) a
student’s t-test P-value of p0.05, (2) a 71.5-fold change
after cisplatin injection, and (3) matched to the preparative
gel (SYPRO ruby-stained gel). These 74 spots were picked
from the SYPRO ruby-stained gel, and their peptide digests
were analyzed by full-scan mass spectrometry (MS) followed
by MS/MS using the matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF)/TOF for protein
identification. Fifteen proteins were identified by MALDI-
TOF/TOF (black numbers, Figure 3a and upper portion of
Table 1). Five proteins increased and 10 proteins decreased
after cisplatin injection (Figure 3b). Four of the identified
proteins were membrane-associated proteins (gray bar in
Figure 3b). Because many of the upregulated (red) spots were
not identified, we re-picked 14 red spots from the SYPRO
ruby gel and the gel plugs were manually digested and
peptides ziptipped for liquid chromatography-MS (LC-MS)/
MS analysis. Thirteen additional proteins were identified
(white numbers, Figure 3a and lower portion of Table 1). By
checking the tandem MS spectra of the corresponding
fragment ions from these peptides, we found that Fetuin-A
had high cross-correlation score (Xcorr¼ 4) and an excellent
MS spectra feature (Figure 4).
We used Western blot analysis to validate these identified
proteins by MALDI-TOF-TOF or LC-MS/MS in urinary
exosomes from individual rats 8 h before and after cisplatin
injection. Of the nine commercially available antibodies (see
Materials and Methods), only the Fetuin-A (increased) and
Annexin V (decreased) results were consistent with the 2D-
DIGE analysis after cisplatin injection. The other proteins
either could not be detected by the available antibodies, or
changed in the opposite direction than that predicted by 2D-
DIGE (data not shown). We selected Fetuin-A as a candidate
biomarker for further.
Temporal urinary excretion of exosomal Fetuin-A in different
types of AKI
We selected Fetuin-A to investigate its temporal excretion
normalized to urine flow rate (per hour) in several renal
injury models based on our observation that it increased
during the early phase of cisplatin-induced AKI. Urinary
Fetuin-A increased 2.75-fold at 24 h after cisplatin injection,
peaked 52.5-fold at day 2 after cisplatin injection, and
remained elevated (51.5-fold) until day 5 compared to
normal urine samples (Figure 5a). We found that Fetuin-A
was detected 2 days before the occurrence of SCr increase and
tubular damage (Figures 1 and 2). We verified that the upper
two of these multiple bands were Fetuin-A when compared to
bovine Fetuin-A as a positive control and pre-adsorbing
antibody with Fetuin-A agarose as a negative control
(Supplementary Figure 8a). Urinary exosomal Fetuin-A also
increased significantly 2–8 h after 15, 30, and 40 min of I/R,
then remained at an elevated level in the 8–24 h collection.
And also, the abundance of urinary Fetuin-A was correlated
positively to the level of SCr at 24 h after I/R (Figure 5b). In
addition, a 31.6-fold of average increment was observed in
urinary Fetuin-A 2–8 h after 37 min I/R (Supplementary
Figure 8b). We also examined urinary Fetuin-A in prerenal
azotemia rats and normal rats as controls. Fetuin-A was not
detected in 1 h urine collection in both groups of rats (Figure
5c). After increasing protein loading and increasing the
exposure time, Fetuin-A could be detected, but was not
different between normal and prerenal azotemic rats
(P¼ 0.7) (Supplementary Figure 8c). To compare the
expression of urinary Fetuin-A in the different models of
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Figure 3 | 2D-DIGE and the fold change of urinary exosome-
associated proteins of rats before and after cisplatin injection.
Urinary exosome-associated proteins were isolated from pooled 8 h
urine samples from 12 rats before and after cisplatin injection.
(a) 2D-DIGE shows increase (red), decrease (green), or no change
(yellow) in abundance of exosome-associated proteins after cisplatin
injection. Black numbers were spots identified by MALDI-TOF-TOF,
white numbers were spots identified by LC-MS/MS. (b) Fold change
of urinary exosome-associated proteins that were increased or
decreased after cisplatin. The gray bars are membrane-associated
proteins. (a) Numbers (1–15) match the black numbers in 2D-DIGE.
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AKI, we selected one rat from each of the three AKI models
(pre-, day 0, 1, and 2 after cisplatin injection; pre- and 2–8 h
after I/R; pre- and 24–30 h after VD) and loaded 1 h
collections of urinary exosomal proteins on a single gel to
reduce the bias created from separate gels. Urinary Fetuin-A
was only detected in the early phase of cisplatin- or I/R-
induced AKI but not in VD animal. The trend of Fetuin-A is
the same as the separate gels (Figure 5c).
Distribution of Fetuin-A in urine
Fetuin-A is synthesized in liver and secreted in blood. We
hypothesized that blood Fetuin-A might be filtered at the
glomerulus, escape tubular reabsorption, and hence appear in
a soluble non-exosomal fraction. Alternatively, Fetuin-A
could be excreted in detached epithelial cells and appear in
the cast fraction. We checked these urinary compartments
using urine samples from day 2 after cisplatin injection,
which had high levels of exosomal Fetuin-A. First, we isolated
proteins from the cast fraction (17 000 g pellet) and
exosome fraction (200 000 g pellet) by differential centri-
fugation; proteins from whole urine, 17 000 g supernatant,
and 200 000 g supernatant (exosome-free fraction) were
precipitated. By Western blot analysis, most of urinary
Fetuin-A appeared in the urinary exosome fraction; only a
small amount of Fetuin-A was detected in urinary casts
(Figure 6a). Then, we compared the effect of washing the
200 000 g pellets with isolation solution to remove free,
soluble Fetuin-A that could possibly adhere to the outer
surface of vesicles. No difference of urinary exosomal Fetuin-
A was found between 200 000 g pellets with and without
washing (Figure 6b). Finally, immunoelectron microscopy
(IEM) was used to determine whether urinary Fetuin-A is
located inside of urine vesicles. Fetuin-A was found inside of
urine vesicles (Figure 6c). In contrast, no positive stained
particles were detected inside or outside of urinary vesicles in
negative control samples (data not shown). Taken together,
these studies demonstrated that Fetuin-A was mostly excreted
in the exosome fraction of urine.
Location of Fetuin-A in rat kidney during development of AKI
Fetuin-A was not detected by immunohistochemical exam-
ination in normal kidney on day 1 after cisplatin injection
and was barely detectable in the cytoplasm of tubule
epithelial cells in the OSOM staining on day 2 after cisplatin
injection (Figure 7a and b). The staining of Fetuin-A
increased significantly in proximal tubular cells with normal
Table 1 | Proteins identified by MALDI-TOF-TOF and LC-MS/MS
Spot Protein identified by MALDI-TOF-TOF MW pI
1 Salivary and hepatic alpha-amylase (a-amylase) 58 6.5
2 b-Glucuronidase precursor 75 6.3
3 Glucan glucanohydrolase 58 7.2
4 Serum amyloid P-component precursor (SAP) 26 5.5
5 Serum albumin precursor 71 6.1
6 Annexin IV 36 5.3
7 Chloride intracellular channel protein 1(NCC27) 27 5.1
8 Annexin V (Anchorin CII) 36 4.9
9 Malate dehydrogenase, cytoplasmic (MDH) 36 6.2
10 Actin, cytoplasmic 1 (b-actin) 42 5.3
11 Heat-shock cognate 71 kDa protein (HSP70) 71 5.4
12 Regucalcin (Senescence marker protein 30) 34 5.3
13 V-ATPase 69 kDa subunit 1 69 5.6
14 Enolase 1 47 6.2
15 (GSH-S) synthetase 53 5.5
New hits Protein identified by LC-MS/MS MW pI Spots in 2-D map
1 Keratin, type II cytoskeletal 8 54 5.8
Type II cytoskeletal 1b 57 5.5
Type I cytoskeletal 21 49 5.3 Identified in spots 1–14
2 ANXA2_RAT Annexin A2 (Annexin II) (Lipocortin II) 38 5.7 Spots 2, 3, 5
3 EF1A2_RAT Elongation factor 1-alpha 2 (EF-1-alpha-2) 50 9.1 Spot 1
4 KPYM_RAT Pyruvate kinase, isozymes M1/M2 57 6.6 Spot 3, 5
5 RAT Histone H2B, 14 10.3 Spot 2
Histone H4 11 11.4 Spot 8, 11
6 MYH9_RAT Myosin heavy chain, nonmuscle type A 23 5.5 Spot 2
7 NHERF_RAT Ezrin-radixin-moesin binding phosphoprotein 50 39 5.7 Spot 3
8 MUP_RAT Major urinary protein precursor (MUP) 21 5.8 Spot 10
9 PCLO_RAT Piccolo protein (Multidomain presynaptic cytoma) 55 6.1 Spot 10
10 FETUA_RAT Alpha-2-HS-glycoprotein precursor (Fetuin-A) 37 6.1 Spot 12, 13
11 GFAP_RAT Glial fibrillaryacidic protein, astrocyte 50 5.4 Spot 12
12 GSH0_RAT Glutamate – cysteine ligase regulatory subunit 31 5.4 Spot 8
13 Serum amyloid P-component precursor (SAP) 2.6 5.5 Spot 7, 8, 9
GSH, glutathione; LC-MS, liquid chromatography-mass spectrometry; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; MW, molecular weight;
pI, isoelectric point.
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Figure 4 | Identification of Fetuin-A protein by LC-MS/MS. MS2 spectra of a Fetuin-A peptide (sequence: LGGEEVSVACK). The red peaks
indicate matched b-ion series, the blue peaks indicate matched y-ion series, and the black peaks indicated unmatched ions. The majority
of peaks are matched in agreement with the high cross-correlation score (Xcorr¼ 4).
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Figure 5 | Temporal excretion of urinary exosomal Fetuin-A in AKI animal models and human subjects by Western blotting analysis.
(a) Cisplatin-induced AKI rats (typical result from three replicates), (b) I/R-induced AKI rats (in 15, 30, and 40 min of bilateral I/R), (c) one blot
of above three types of AKI rats (one rat pre-, day 0, day 1, and day 2 after cisplatin injection; one rat from pre- and 8 h after I/R; one rat from
pre- and 24–30 h after VD), and (d) ICU patients with and without AKI compared to healthy volunteers.
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structure and few damaged tubules on day 3 (Figure 7c); no
positive staining was detected in the day 3 kidney sections
with renal structural injury when primary Fetuin-A antibody
was used instead of normal donkey serum (Figure 7e); and
then was expressed highly in the detached tubular cells in the
tubule lumen on day 5 after cisplatin injection (Figure 7d).
After I/R, positive staining of Fetuin-A increased significantly
in partially damaged proximal tubule cells at 8 h and was
restricted to the detached cells in the lumen by 24 h after the
surgery compared to the sham kidney (Figure 7f–h).
Urinary exosomal Fetuin-A in ICU patients
Spot urine samples were collected and stored at 801C from
three healthy volunteers (age 34–43 years), three ICU patients
with AKI, and three ICU patients without AKI. The clinical
details of the ICU patients are listed in Table 2. We isolated
exosome-associated proteins from these urine samples and
examined the abundance of Fetuin-A normalized by urine
creatinine using Western blot analysis. Urinary exosomal
Fetuin-A increased significantly in ICU patients with AKI
compared to either healthy volunteers or ICU patients
without AKI (Figure 5d).
DISCUSSION
Urine is an ideal source for discovery of non-invasive
biomarkers and it is likely that multivariable assessment
tools that incorporate both biomarkers and clinical informa-
tion can enhance the diagnostic and predictive accuracy in a
complex disease such as AKI.5 Recently, it has been suggested
that proteomic techniques including high-throughput iden-
tification of proteins may be useful to discover urinary
biomarkers for various kidney diseases.23,24 These methods
have thus far identified that abundant proteins or well-
known proteins such as albumin, transferrin, and a-1-anti-
trypsin are increased in glomerular diseases;24 and urinary
b2 microglobulin, retinol-binding protein, and carbonic
anhydrase are increased in acute renal allograft rejection.25
However, these abundant proteins lack specificity for
diagnosis of disease and impede the discovery of new
biomarkers, especially in glomerular diseases. It has been
Original urine
volume ( l)
800 800 40 800800
59 kDa
1 2 3 4 5 1 2a
c
b
100 nm
Figure 6 | The distribution of Fetuin-A in rat urine 2 days after
cisplatin injection. (a) The secretion of Fetuin-A in different urinary
fractions from the same urine sample (lane 1: 200 000 g pellets, lane
2: 17 000 g pellets, lane 3: whole urine, lane 4: 17 000g
supernatant, and lane 5: 200 000g supernatant) by Western blot
analysis. The lower label indicates the original volume of urine used
for each lane. (b) Comparison of urinary exosomal Fetuin-A in the
200 000 g pellets without and with washing by isolation solution
(lane 1: unwashed pellet; lane 2: washed pellets). (c) Fetuin-A located
inside of urinary vesicles in 200 000 g pellets by IEM. Bar¼ 100 nm.
Inset shows a magnified image of a urinary vesicle labeled with
gold-conjugated anti-Fetuin-A.
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Figure 7 | Location of Fetuin-A in OSOM of rat kidney. Left panels:
Temporal immunohistochemistry staining for Fetuin-A in OSOM of
kidneys (a) before and at (b) day 2, (c) day 3, and (d) day 5 after
cisplatin injection in rats. Right panel: (e) Negative control (injured
kidney section at day 3 after cisplatin injection), Sham surgery for
(f) I/R, I/R rats at (g) 8 h, and (h) 24 h after I/R. Original
magnification 400.
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hypothesized that the low abundance urinary proteins might
be better targets for biomarker discovery.26 However, the
removal of interfering abundant proteins might also remove
less abundant proteins that bind to the abundant proteins.
Recently, exosomes containing both membrane and
cytosolic proteins were isolated from normal human urine
by differential centrifugation, and exosomal proteins related
to kidney diseases were identified by LC-MS/MS.7 Exosomal
protein biomarkers might be clinically useful biomarkers; Du
Cheyron et al.17 reported that sodium/hydrogen exchanger
isoform 3, a membrane protein, increased in acute tubule
necrosis patients but not in prerenal azotemia or acute
glomerular diseases. We thought that this urinary compart-
ment, containing a reduced protein complexity and depleted
predominant proteins, might be used for biomarker
discovery, particularly for proteins that might indicate
structural renal disease.
We investigated urinary exosomes from cisplatin-induced
AKI rats for biomarker discovery by 2D-DIGE. We could
identify only 20% of the picked spots, and only 26% of the
identified proteins were membrane-associated proteins,
potentially caused by insufficient solublization, limited access
to trypsin sites, or low abundance of membrane proteins. We
also had great difficulty validating the DIGE results, perhaps
owing to the pitfalls inherent in 2D analysis, including
changes in spot position owing to post-translational
modification or the presence of multiple proteins per spot,
or to insensitive antibodies. Further research to more
effectively solubilize membrane proteins, optimize analytical
protocols, and improve the detection of post-translational
modifications will be required to overcome these current
limitations in the proteomics field.
Nevertheless, we did find that one excreted exosomal
protein, Fetuin-A (P24090), that was increased after renal
injury and could be validated by Western blotting. Two red
spots (spots 12 and 13) that were increased after cisplatin
injection were identified as Fetuin-A by LC-MS/MS on the
third survey of the gel. However, the position of these spots
on the 2D gel did not match the predicted molecular weight
and isoelectric point. We hypothesize that cleavage of Fetuin-
A occurred before 2D electrophoresis and that intact Fetuin-
A with correct molecular weight and isoelectric point was not
seen because Fetuin-A is highly glycosylated. Fetuin-A, also
known as alpha-2-HS-glycoprotein (NP_001613), was iden-
tified by MALDI-TOF MS in a previous proteomic analysis of
human urinary proteins isolated by acetone precipitation.27
However, Fetuin-A was not identified by MALDI-TOF MS or
LC-MS/MS in normal urinary exosomal proteins isolated by
ultracentrifugation from either human7,27 or male Sprague–-
Dawley rats.28
We found that most of urinary Fetuin A was detected in
the 200 000 g pellet. Only a small amount was in the
17 000 g pellet, and none was detected in the supernatant of
200 000 g after AKI. Washing the 200 000 g pellet to
remove bound Fetuin-A that could adhere to the outer
surface of vesicles, did not affect the abundance of urinary
Fetuin-A. Moreover, IEM revealed Fetuin-A located inside of
urinary vesicles; a previous study also demonstrated that
Fetuin-A is located in the vesicles from culture medium of
human vascular smooth muscle cells.29
The quantification of Fetuin-A identified by 2D DIGE was
validated by the low abundance or lack of Fetuin-A in normal
urine and kidney when compared to the large increase in
urine and kidney in animal models of cisplatin and I/R, and
in human ICU patients with AKI. Fetuin-A increased 2 days
earlier than SCr in cisplatin-induced AKI and before SCr
increased in I/R-induced AKI. Urinary Fetuin-A was
detectable 1 day before recognition of morphological injury
and remained high, whereas structural renal injury was
present morphologically. Fetuin-A did not increase following
VD (prerenal azotemia), which is sometimes difficult to
differentiate from structural renal injury in the clinic. Urinary
Fetuin-A showed a similar spectrum compared to the other
current early urinary biomarkers in AKI models, such as
kidney injury molecule-1, NGAL, interleukin-18, and NAG.5
However, Fetuin-A has two interesting characteristics: (1) it
has a very large dynamic range, similar to NGAL, but much
larger than kidney injury molecule-1, and (2) the modestly
delayed onset in cisplatin, compared to the immediate increase
of other markers such as NGAL, suggests that Fetuin-A might
be useful to detect structural injury, not early renal response to
injury. Taken together, the pre-clinical animal data suggest that
urinary exosomal Fetuin-A might serve as an additional
urinary biomarker to predict structural renal injury.
We also found that urinary exosomal Fetuin-A was much
higher in ICU patients with AKI compared to faint
Table 2 | Characteristics of ICU patients in the study
Patients
Age/
gender Primary diagnosis
APACHE II
score AKI
Serum
creatinine
(mg/dl)
Blood urea
nitrogen
(mg/dl)
Urine
output
(ml/day)
Furosemide
(mg)
Blood
culture SIRS Sepsis WBC Temperature
1 86/M MI, AKI, pneumothorax 22 Yes 2.0 36 207 100 No No No 11.79 37.3
2 67/M COPD lung cancer AKI 14 Yes 3.4 89 477 80 No No No 17.86 37.4
3 37/M Pneumonia, ARDS 21 Yes 2.1 54 2381 None No Yes Yes 2.9 38.2
4 50/F Meningitis 10 No 0.8 11 2468 None Yes (+) Yes Yes 12.46 37.8
5 42/M Pneumonia 9 No 0.6 11 2135 20 No Yes No 14.77 38.5
6 41/F DM, necrotizing, fascitis 17 No 0.4 16 1617 None Yes (+) Yes Yes 10.76 38.7
AKI, acute kidney injury; APACHE II, acute physiology and chronic health evaluation; ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease;
DM, diabetes mellitus; F, female; ICU, intensive care unit; M, male; MI, myocardial infarction; SIRS, systemic inflammatory response syndrome; WBC, white blood cell.
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expression of Fetuin-A in ICU patients without AKI, and was
not detected in the urine exosome fraction of healthy
volunteers, consistent with the previous study.7 Mortality
and morbidity of sepsis-induced AKI in ICU remains high. A
simple urinary biomarker has limitations in a complex
population such as ICU patients with AKI. Sepsis-induced
AKI is often difficult to diagnose because patients are
volume expanded, which depresses SCr, and the fractional
excretion of sodium may be low despite irreversible renal
injury.30 Recent studies have found that urinary NGAL
increased 2 h after cardiac surgery and can accurately predict
AKI in children; however, it does not perform as well in
adult ICU patients with multifactorial AKI.12 Urinary
interleukin-18 increased at 4–6 h after cardiac surgery31
and also increased 24 h before SCr in ICU patients with
AKI. Both urinary NGAL and interleukin-18 could also
partially predict the outcome of AKI.16 Du Cheyron et al.17
reported that urinary sodium/hydrogen exchanger isoform 3
isolated by ultracentrifugation could distinguish acute
tubule necrosis from other forms of AKI. It is likely that a
panel of biomarkers, along with associated clinical informa-
tion, will be required for early and accurate diagnosis
of ICU patients with AKI. Our current studies suggest that
urinary exosomal Fetuin-A might be useful in human AKI;
however, additional studies will be needed to determine
whether urinary Fetuin-A can predict, diagnose, track
treatment effects, evaluate severity or prognosis in a large
number of ICU patients and patients with typical acute
tubule necrosis.
Possible mechanism of why urinary exosomal Fetuin-A
is increased in AKI
Fetuin-A is synthesized in liver and secreted into the blood
stream, where it is a negative acute-phase response protein
and plays its anti-inflammatory role via suppressing release
of tumor necrosis factor-alpha induced by lipopolysaccharide
in vitro and vivo.32 Fetuin-A is also a systemically acting inhi-
bitor of ectopic calcification,33 and decreased serum Fetuin-A
concentration is associated with a higher mortality rate in
dialysis patients and can predict mortality of chronic kidney
diseases.34,35 High plasma Fetuin-A levels are correlated with
insulin resistance and fatty liver in human36 and are also
independently associated with metabolic syndrome in non-
diabetic outpatients with coronary artery disease.37 However,
the function of Fetuin-A in AKI is unknown.
We hypothesized that increased urinary exosomal Fetuin-
A might be secreted from proximal tubule cells. A previous
study reported that Fetuin-A was located in the developing
kidney tubule in rat embryo by immunohistochemical
staining.38 In this study, Fetuin-A was located in the
cytoplasm of damaged proximal tubules that were attached
on the basement membrane and at even higher concentration
in proximal tubule cells that had detached from the tubule
basement membrane. Although exosomal Fetuin-A may be
synthesized by the kidney, it may also appear in the urine as a
result of incomplete proximal tubule processing in protein-
uria states (a form of overflow proteinuria) or released
during tubular cell apoptosis. Fetuin-A was detected in
apoptotic vascular smooth muscle cells,29 and apoptotic cells
have been demonstrated in tubular cells in cisplatin- or I/R-
induced AKI in animals.39–41 We did not find evidence for
free Fetuin-A that was filtered at the glomerulus, at least in
the settings examined.
Conclusion
Proteomic methods can be used to discover candidate
urinary biomarkers for AKI, although the process in the
present study is more difficult because of inefficiencies at the
proteome identification and antibody recognition steps.
Urinary exosomal Fetuin-A is increased in AKI, but not in
prerenal azotemia. Urinary exosomal Fetuin-A is elevated in
patients with AKI in ICU. Determination of the clinical value
of urinary Fetuin-A requires further study in a large number
of patients.
MATERIALS AND METHODS
AKI models and urine collection
Male Sprague–Dawley rats were purchased from Harlan Sprague–-
Dawley Inc. (Indianapolis, IN, USA). All animals had free access to
water and standard food, and were treated in accordance with the
National Institute of Health guidelines for use and care of research
animals. All urine samples from animals were collected using
protease inhibitors in metabolic cages and then stored at 801C,
until the isolation of exosome-associated proteins as described
previously.6
Cisplatin-induced AKI (n¼ 151): Rats (250–280 g; 8 weeks) were
given by a single intravenous injection of cisplatin (6 mg/kg body
weight) (Sigma Corp, St Louis, MO, USA). Blood samples from the
abdominal aorta were collected in 56 rats under isoflurane
anesthesia before cisplatin (day 0) and at 1, 2, 3, 5, 7, 10, and 14
days after cisplatin injection. Urine samples were collected from 12
rats before (24 to 16 h) and 0–8 h after cisplatin injection and
pooled for biomarker discovery by proteomics analysis. We then
collected urine samples from four individual cisplatin-treated rats
for validation of the identified proteins. A second set of temporal
urine samples were collected on 0–5 days from three additional rats
for validation of Fetuin-A. Urine samples were also collected at day 2
after cisplatin injection for examining urinary IEM.
I/R-induced AKI (n¼ 12): Rats (180–210 g; 7 weeks) were
subjected to respective 15, 30, and 40 min bilateral I/R and sham
surgery (n¼ 4) as described previously.19 Urine samples were
collected at 2–8 and 8–24 h after I/R. Additional eight rats were
subjected to 37 min I/R for temporal urine collections at 24 to
18 h before I/R and 2–8 h and 8–24h after I/R. The rats were killed
at 8 or 24 h after I/R for the collection of blood samples and kidney
tissues.
VD (n¼ 4): Rats (380–400 g; 14 weeks) were fed a low-salt diet
(0.03%) (Diet Test Inc., Philadelphia, PA, USA) 18 h before
intraperitoneal injection of furosemide as described previously.19
We collected 6 h urine samples from four rats at 24 to 18 h
before and 24–30 h after VD. Rats were killed at 33 h after
furosemide injection for blood collection.
Human samples: To verify the clinical potential of Fetuin-A, we
also collected spot human urine samples from three healthy
volunteers, three ICU patients with AKI, and three ICU patients
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with and without AKI and sepsis. Samples were collected at George
Washington University Intensive Care Unit under approval of the
GW Institutional Review Board (Protocol 090013ER).
Examination of renal function
SCr was measured by picric acid-based colorimetric autoanalyzer
(Astra 8 autoanalyzer; Beckman Instruments, Fullerton, CA, USA)
and blood urea nitrogen by an autoanalyzer (Hitachi 917,
Boehringer Mannheim, Indianapolis, IN, USA). The kidneys
were examined for histology and immunohistochemistry. The
harvested left kidney from each animal was immediately fixed in
10% neutral buffered formalin solution. The kidney tissue block was
dehydrated through a graded alcohol series, embedded in paraffin,
and cut into 4-mm sections and then stained with periodic acid
Schiff reagent.
Isolation of urinary exosome-associated proteins
and depletion of Tamm–Horsfall protein
Urine samples were extensively vortexed immediately after they
thawed. Urinary exosome-associated proteins were isolated by
differential centrifugation (17 000 g 15 min to remove urinary
sediment then 200 000 g 1 h pellet) as described previously.6,7 The
exosome-associated proteins isolated from the pooled urine samples
were suspended by isolation solution (10 mM triethanolamine,
250 mM sucrose (pH 7.6)). To partially deplete the abundant
Tamm–Horsfall protein, the suspensions were incubated with
reducing agent dithiothreitol (200 mg/ml) at 951C for 2 min, and
the samples were ultracentrifuged again. This procedure was
repeated a second time, allowing the denatured Tamm–Horsfall
protein to be released into the supernatant.7 The high-spin pellets
were solubilized in 2D lysis buffer (7 M urea, 2 M thiourea, 4%
CHAPS, and 15 mM Tris (pH 8.5)) for 2D proteomic analysis. The
concentration of protein was measured by 2D quant protein assay
(Amersham, Piscataway, NJ, USA). For Western blot analysis,
exosome-associated proteins were isolated from individual rat urine
samples and suspended by isolation solution. For comparison with
urinary exosome fraction, acetone precipitation was used to concen-
trate the soluble protein in whole urine, 17 000 g supernatant, and
200 000 g supernatant.6
Proteomics methods
Two-dimensional difference in gel electrophoresis. 2D gels
were run in triplicate. Four hundred picomoles of CyDye were used
to label 50 mg of protein as suggested in the manufacturer’s protocol:
pre-cisplatin proteins were labeled with Cy 3; post-cisplatin proteins
with Cy 5; a mixture of both proteins were labeled with Cy 2 as an
internal standard. After quenching the reaction with 10 mM of lysine,
the labeled samples were mixed together and rehydration buffer was
added (7 M urea, 2 M thiourea, 4% CHAPS, 1% ampholytes pH
3-10NL (Amersham), 40 mM dithiothreitol, and 0.0002% bromo-
phenol blue). We also added 750mg of unlabeled protein mixture in
another gel for SYPRO ruby staining in order to obtain protein
identification. We normalized the loading proteins with and without
cisplatin treatment by collection time. The mixed samples were run
in triplicate, loaded on an immobilized pH gradient strip (24 cm;
pH 3-10NL) for isoelectric focusing according to the following
protocol: 30 V for 14 h (active rehydration), 500 V for 500 V h,
1000 V for 1000 V h, and 8000 V for 66 667 V h. Each strip was
equilibrated for 15 min in a equilibration solution containing 50 mM
Tris-HCl (pH 8.8), 6 M urea, 30% glycerol, 2% sodium dodecyl
sulfate, 0.002% bromophenol blue with 0.5% dithiothreitol followed
by a second 15 min equilibration with iodoacetamide (4.5%). Strip
were briefly rinsed in 1 sodium dodecyl sulfate-polyacrylamide
gel electrophoresis buffer and applied to a 12.5% polyacrylamide gel
for electrophoresis at 5 W/gel for 30 min followed by 17 W/gel for
4 h, 151C.
Image acquisition and analysis. CyDye-labeled gels were
scanned on a Typhoon 9400 variable mode imager (Amersham
Biosciences, Piscataway, NJ, USA) at an excitation wavelength of
520/40 (maximal/bandwidth) for Cy2- (laser-blue), 580/30 for Cy3-
(laser-green), or 670/30 for Cy5- (laser-red) labeled samples. The
photo multiplier tube (PMT) setting was adjusted to avoid signal
saturation. The image resolution was 100 mm. Images were then
processed with Decyder Biological Variation Analysis module v5.01
software (Amersham Biosciences) to match multiple 2D-DIGE gels
for comparison and statistical analysis of protein abundance changes
by spot fluorescence intensities. After protein spots were designated
to be picked, the gel with 750 mg protein was fixed in 30% methanol
and 7% acetic acid for 1 h and incubated in SYPRO ruby protein gel
stain (Bio-Rad Laboratories, Hercules, CA, USA) overnight. The
pick gel was then washed three times with ultrapure water
(Millipore, Billerica, MA, USA) for 10 min each wash. Next, the
gel was scanned at an excitation wavelength of 610/30 to visualize all
proteins in the gel. CyDye- and SYPRO-derived images were
matched using Biological Variation Analysis software, from which a
pick list was generated.
Spot picking and protein identification. An automated Ettan
Spot Handling Workstation (GE healthcare, Piscataway, NJ, USA)
was used for gel-spot picking, in-gel protein digestion with trypsin,
and spotting on MALDI plates, as described previously.42 Peptides
were analyzed using the Proteomics Analyzer (ABI 4700 MALDI-
TOF/TOF). Full-scan MS spectra were obtained first, followed by
MS/MS spectra. Protein identification was carried out using the
search engine, MASCOT (Matrix Science, Boston, MA, USA). An
additional 14 spots not identified by MALDI-TOF-TOF were picked
with the Ettan Spot Handling Workstation then manually digested
with trypsin and desalted with C18 Ziptips (Millipore, Billerica, MA,
USA). The extracted peptides were analyzed using the Finnigan
LTQ mass spectrometer (Thermo Electron, San Jose, CA, USA),
according to the published procedure.43
Western blot analysis
Exosome-associated protein samples (from urine samples of the
same time for each rat) were separated by 1D sodium dodecyl
sulfate/polyacrylamide gel electrophoresis and then gels were
transferred to polyvinylidene difluoride membranes. After blocking
with 5% milk (1 h), membranes were probed overnight at 41C with
antibodies: rabbit polyclonal antibodies to Fetuin-A (1:500) (Novus
Biologicals, Littleton, CO, USA), a-Amylase (1:5000) (Rockland,
Gilbertsville, PA, USA), serum Amyloid P (1:1000) (Abcam Inc.,
Cambridge, MA, USA), Annexin V (2 mg/ml) (Abcam), neuron
specific enolase (1:1000) (Biogenesis Inc., Kingston, NH, USA);
mouse monoclonal antibodies to b-Glucuronidase (1:50) (Cell
Sciences, Canton, MA, USA), Regucalcin (1:500) (Cell Sciences),
Annexin IV (1:1000) (BD Biosciences Pharmingen, San Diego, CA,
USA); sheep polyclonal anti-MDH (1:4000) (Rockland). Peroxidase-
conjugated, affinity-purified donkey anti-rabbit, anti-mouse, or
anti-sheep immunoglobulin G (1:100 000) (Jackson Immuno-
Reseach, West Grove, PA, USA) were used for 90 min at room
temperature. The antibody–antigen reactions were visualized by
using enhanced chemiluminescence plus Western blotting detection
system (Amersham Biosciences) and light-sensitive film (Kodak
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BioMax XAR, Rochester, NY, USA). For quantification of band
intensity, National Institute of Health Image software was used. To
verify the true bands of Fetuin-A, we loaded duplicate of serial
dilution of bovine Fetuin-A (Sigma Aldrich, St Louis, MO, USA) as
a positive control and urinary exosomal proteins from a cisplatin-
treated rat at day 3 on one gel and then gel was transferred to
polyvinylidene difluoride membrane. The membrane was cut into
two parts with same protein samples. One was probed with Fetuin-A
antibody and another was probed with pre-adsorbed Fetuin-A
antibody as a negative control with Fetuin-A agarose, immobilized
on cross-linked 4% beads agarose (Sigma Aldrich) and then
followed by the above procedure.
IEM of urinary Fetuin-A
A 200 000 g pellet was obtained from 8 h urine samples of rats
2 days after cisplatin injection. The suspension was mixed 1:1 with
4% paraformaldehyde and then applied to 200-mesh nickel grids.
After blocking with 1% bovine serum albumin and washing, the grid
was incubated with polyclonal rabbit anti-Fetuin-A (1:500) (Novus)
containing 0.02% Triton X-100 (to permeabilize the vesicle
membrane) and only antibody solution for 45 min at room
temperature. Then, the grids were exposed to goat anti-rabbit
immunoglobulin G (1:40) conjugated with 6 nm colloidal gold
particles (12 nm) (1:40, Jackson ImmunoResearch) for 60 min at
room temperature. After washing, membranes were negatively
stained with 0.5% uranyl acetate. After drying, the grids were
examined with a JEOL 1200 EX electron microscope operated at
60 kV.
Immunohistochemical examination of Fetuin-A
The paraffin-embedded kidney blocks were cut at 4 mm thickness,
deparaffinized, and rehydrated. After consuming endogenous
peroxidase with 3% H2O2, slides were pre-incubated with 10%
normal donkey serum to block nonspecific reactions and then
incubated with polyclonal rabbit anti-Fetuin-A (1:150) (Novus)
overnight at 41C. The slides were followed by incubation with
biotin-conjugated donkey anti-rabbit immunoglobulin G (1:1000)
(Jackson ImmunoReseach) for 30 min at room temperature, and
then reacted with streptavidin-conjugated peroxidase (Dako Corp.,
Carpinteria, CA, USA) for 30 min at room temperature. The
reaction products were visualized using a DAB kit (Vector
Laboratories Inc., Burlingame, CA, USA).
Statistical analysis
All data are expressed as mean7s.e.m. Differences between groups
were analyzed for statistical significance by t-test. A P-value o0.05
was accepted as statistically significant.
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